jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Eisai Co Ltd

Recent news which mentions Eisai Co Ltd

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Tags Biogen Inc Health care industry Companies
From CNBC.com News
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Tags Biogen Inc Health care industry Companies
From CNBC.com News
5 things to know before the stock market opens Monday
Tags Biogen Inc Technology Economy
From CNBC.com News
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
Tags Biotech and Pharmaceuticals Pharmaceuticals Breaking News: Business
From CNBC.com News
Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
Tags Companies Breaking news Biogen Inc
From CNBC.com News
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
Tags Breaking news Companies Health care industry
From CNBC.com News
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
Tags Business News Pharmaceuticals Biotech and Pharmaceuticals
From CNBC.com News
Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
Tags Mad Money Investment strategy Markets
From CNBC.com News
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Tags Companies Breaking news Biogen Inc
From CNBC.com News
Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
Tags Health care industry Biogen Inc Companies
From CNBC.com News
Healthy Returns: The launch of breakthrough Alzheimer’s drug Leqembi is off to a slow start
Tags Biotech and Pharmaceuticals Science Health care industry
From CNBC.com News
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
Tags Health care industry Biogen Inc Breaking news
From CNBC.com News
Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Tags Health care industry Pharmaceuticals Biotech and Pharmaceuticals
From CNBC.com News
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Tags Business News Pharmaceuticals Biotech and Pharmaceuticals
From CNBC.com News
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops
Tags Business News Biotech and Pharmaceuticals Pharmaceuticals
From CNBC.com News
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study
Tags Breaking news Companies Health care industry
From CNBC.com News
5 things to know before the stock market opens Tuesday
Tags Technology Biogen Inc Economy
From CNBC.com News
Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year
Tags Business News Biotech and Pharmaceuticals Pharmaceuticals
From CNBC.com News
Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know
Tags Health & Science Eisai Co Ltd Business
From CNBC.com News
Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024
Tags Eisai Co Ltd Biotechnology Business
From CNBC.com News
Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more
Tags DraftKings Inc Alibaba Group Holding Ltd Levi Strauss & Co
From CNBC.com News
Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug
Tags Biogen Inc Asia Markets Pharmaceuticals
From CNBC.com News
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage
Tags Eisai Co Ltd Biotechnology Business
From CNBC.com News
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
Tags Health care industry Pandemics U/S/ Economy
From CNBC.com News
Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action
Tags Social issues Politics US Economy
From CNBC.com News
Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates
Tags Politics U/S/ Economy Health care industry
From CNBC.com News
Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments
Tags Politics World News US Economy
From CNBC.com News
Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
Tags Business News Breaking News: Business Disease outbreaks
From CNBC.com News
Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says
Tags U/S/ Economy Health care industry Pandemics
From CNBC.com News
Biogen isn't concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
Tags Companies Breaking news Biogen Inc
From CNBC.com News
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News